These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33247691)

  • 1. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
    Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
    Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
    Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
    Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
    BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
    Zhou Y; Feng FZ; Xiang Y; Wan XR
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
    Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
    J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
    Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
    Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
    Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.
    You B; Harvey R; Henin E; Mitchell H; Golfier F; Savage PM; Tod M; Wilbaux M; Freyer G; Seckl MJ
    Br J Cancer; 2013 May; 108(9):1810-6. PubMed ID: 23591194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
    You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
    Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
    Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
    ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
    Cavoretto P; Gentile C; Mangili G; Garavaglia E; Valsecchi L; Spagnolo D; Montoli S; Candiani M
    Ultrasound Obstet Gynecol; 2012 Jul; 40(1):99-105. PubMed ID: 22262502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.